Projected Benefits of Long-Acting Antiretroviral Therapy in Nonsuppressed People With Human Immunodeficiency Virus Experiencing Adherence Barriers.

Wanyi Chen Monica GandhiPaul E SaxAnne M NeilanWendy H GarlandTimothy WilkinRebecca CohenAndrea L CiaranelloSonali P KulkarniJoseph EronKenneth A FreedbergEmily P Hyle

Published in: Open forum infectious diseases (2023)

These model-based results support that long-acting injectable CAB-RPV with extensive support services for nonsuppressed PWH experiencing adherence barriers is likely to increase viral suppression and improve survival. A prospective study to provide further evidence is needed.

Keyphrases

human immunodeficiency virus
antiretroviral therapy
hiv infected
hepatitis c virus
hiv positive

hiv infected patients
hiv aids
healthcare
primary care

sars cov
mental health
climate change
glycemic control

type diabetes
south africa
adipose tissue
free survival